Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials
ReutersNov 24, 2025 12:00 PM
Shares of Biogen BIIB.O rise 5.1% to $184.25 premarket
Novo Nordisk NOVOb.CO says its diabetes drug Rybelsus failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patients
The study was keenly watched as an indication of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's
Biogen and partner Eisai's 4523.T Leqembi and rival Eli Lilly's LLY.N Kisunla are the only approved treatments for Alzheimer's in the U.S.
The Danish drugmaker's Rybelsus and blockbuster drugs Ozempic and Wegovy are based on the same active ingredient, semaglutide
Up to last close, Biogen has gained ~15% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Fed Officials Speak Out in Force to Back Rate Cut! December Cut Now a Done Deal? Will the FOMC Meeting Be Delayed?
TradingKey - San Francisco Fed President Mary Daly has voiced support for a rate cut at next month's Federal Reserve meeting, arguing that a sudden job market deterioration poses a greater and harder-to-manage risk than an inflation surge.TradingKey
6 hours ago
U.S. September PCE: Likely to Fall Short of Expectations, Bullish for US Stocks
TradingKey - Currently, the market widely anticipates that the core PCE year-on-year growth rate for September will stand at 2.9%, and we expect the upcoming data to be slightly below this consensus forecast.TradingKey
12 hours ago
Palantir: Why PLTR Is So Notorious, Its Stock Performance, and If It's a Buy
TradingKey — Palantir Technologies Inc. (PLTR) stock maintains its investment appeal, with analysts recommending buying on dips as valuation corrections and consistently strong earnings bolster its long-term prospects. While short-term volatility is driven by a cooling AI narrative and adjustments tTradingKey
Fri, Nov 21
The U.S. Dollar Index Is the Key Driver of Gold Prices: Where Are the Dollar and Gold Headed Next?
TradingKey - The strength or weakness of the U.S. Dollar Index stands as the core determinant shaping gold's trajectory.TradingKey
Fri, Nov 21
Alibaba FY2026Q2 Earnings Preview: The Great Pivot from E-Commerce Giant to AI Powerhouse
TradingKey - As Alibaba's earnings approach, one question dominates: Can AI and quick commerce justify sacrificing profits now for future dominance? Preview how the RMB 50 billion quick commerce push, 35.8% AI cloud share, and fierce competition could decide if BABA's 88% rally holds.TradingKey
Thu, Nov 20
